CN1956729A - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN1956729A
CN1956729A CNA2005800163224A CN200580016322A CN1956729A CN 1956729 A CN1956729 A CN 1956729A CN A2005800163224 A CNA2005800163224 A CN A2005800163224A CN 200580016322 A CN200580016322 A CN 200580016322A CN 1956729 A CN1956729 A CN 1956729A
Authority
CN
China
Prior art keywords
ova
stxb
antigen
adjuvant
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800163224A
Other languages
English (en)
Chinese (zh)
Inventor
P·肖梅兹
C·P·A·G·科利弄
M·P·范梅歇伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN1956729A publication Critical patent/CN1956729A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800163224A 2004-05-21 2005-05-19 疫苗 Pending CN1956729A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0411411.2A GB0411411D0 (en) 2004-05-21 2004-05-21 Vaccines
GB0411411.2 2004-05-21

Publications (1)

Publication Number Publication Date
CN1956729A true CN1956729A (zh) 2007-05-02

Family

ID=32607764

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800163224A Pending CN1956729A (zh) 2004-05-21 2005-05-19 疫苗

Country Status (16)

Country Link
US (1) US20080069832A1 (https=)
EP (1) EP1761275A2 (https=)
JP (1) JP2007538044A (https=)
KR (1) KR20070029730A (https=)
CN (1) CN1956729A (https=)
AU (1) AU2005244615A1 (https=)
BR (1) BRPI0511185A (https=)
CA (1) CA2564778A1 (https=)
GB (1) GB0411411D0 (https=)
IL (1) IL178890A0 (https=)
MA (1) MA28609B1 (https=)
MX (1) MXPA06013386A (https=)
NO (1) NO20065304L (https=)
RU (1) RU2006139424A (https=)
WO (1) WO2005112991A2 (https=)
ZA (1) ZA200609500B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448485B (zh) * 2009-04-09 2015-01-14 墨尔本大学 免疫原性组合物及其用途
CN105055311A (zh) * 2009-12-03 2015-11-18 诺华股份有限公司 乳液微流化和/或均化期间的组分循环
USRE46906E1 (en) 2009-12-03 2018-06-26 Novartis Ag Methods for producing vaccine adjuvants
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
CN110290806A (zh) * 2016-12-20 2019-09-27 葛兰素史密丝克莱恩生物有限公司 用于诱导免疫应答的新型方法
CN111333734A (zh) * 2020-03-31 2020-06-26 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用
CN113365657A (zh) * 2018-12-18 2021-09-07 禾大国际股份公开有限公司 具有疫苗佐剂效应的丝状纳米颗粒

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
JP2008540625A (ja) * 2005-05-19 2008-11-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｅ．ｃｏｌｉ易熱性毒素のＢ−サブユニット、抗原およびアジュバントを含むワクチン組成物
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
EP1938836A1 (en) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
WO2009126819A1 (en) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease
AU2009344150B2 (en) * 2009-04-09 2014-10-09 Innavac Pty Ltd Immunogenic composition and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
TW201103980A (en) 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CN104688687A (zh) 2009-12-03 2015-06-10 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
US20140234424A1 (en) * 2011-07-22 2014-08-21 Glaxosmithkline Biologicals Sa Prame purification
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
JP5931113B2 (ja) * 2014-04-08 2016-06-08 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
KR101987851B1 (ko) 2017-04-28 2019-06-11 한국생명공학연구원 장출혈성대장균 유래의 시가독소 타입 1 B-subunit으로 유도된 노인성 황반변성(AMD) 동물모델 및 이를 이용한 스크리닝 방법
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138997C (en) * 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
CA2218601A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1078007B1 (en) * 1998-05-15 2005-11-23 Institut Curie Verotoxin b subunit for immunization
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448485B (zh) * 2009-04-09 2015-01-14 墨尔本大学 免疫原性组合物及其用途
CN105055311A (zh) * 2009-12-03 2015-11-18 诺华股份有限公司 乳液微流化和/或均化期间的组分循环
US9750690B2 (en) 2009-12-03 2017-09-05 Novartis Ag Circulation of components during microfluidization and/or homogenization of emulsions
USRE46906E1 (en) 2009-12-03 2018-06-26 Novartis Ag Methods for producing vaccine adjuvants
US10463615B2 (en) 2009-12-03 2019-11-05 Novartis Ag Circulation of components during microfluidization and/or homogenization of emulsions
US11141376B2 (en) 2009-12-03 2021-10-12 Novartis Ag Circulation of components during microfluidization and/or homogenization of emulsions
CN110290806A (zh) * 2016-12-20 2019-09-27 葛兰素史密丝克莱恩生物有限公司 用于诱导免疫应答的新型方法
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
CN113365657A (zh) * 2018-12-18 2021-09-07 禾大国际股份公开有限公司 具有疫苗佐剂效应的丝状纳米颗粒
US12268740B2 (en) 2018-12-18 2025-04-08 Croda International Plc Filamentous nanoparticles having vaccine adjuvant effect
CN111333734A (zh) * 2020-03-31 2020-06-26 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Also Published As

Publication number Publication date
MXPA06013386A (es) 2007-01-23
IL178890A0 (en) 2007-03-08
AU2005244615A1 (en) 2005-12-01
RU2006139424A (ru) 2008-06-27
MA28609B1 (fr) 2007-05-02
KR20070029730A (ko) 2007-03-14
ZA200609500B (en) 2008-02-27
WO2005112991A2 (en) 2005-12-01
US20080069832A1 (en) 2008-03-20
EP1761275A2 (en) 2007-03-14
JP2007538044A (ja) 2007-12-27
BRPI0511185A (pt) 2007-12-04
WO2005112991A3 (en) 2006-03-30
GB0411411D0 (en) 2004-06-23
NO20065304L (no) 2006-11-20
CA2564778A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
CN1956729A (zh) 疫苗
EP2125012B1 (en) Compositions comprising a b subunit of shiga toxin and a means stimulating nkt cells
CN1227030C (zh) 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
JP5667107B2 (ja) ワクチン
CN101068568B (zh) 抗疟疾的初始/加强免疫疫苗
US11285204B2 (en) Tobamovirus-based virus-like particles and vaccines
JP2019070035A (ja) 免疫原およびそのスクリーニング方法
US20090035330A1 (en) Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant
US20100266672A1 (en) Vaccines
US20100196451A1 (en) Vaccines Containing Non-Live Antigenic Vectors
WO2009077436A2 (en) Method for preparing protein conjugates
CN101180075A (zh) 疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070502